Gujarat Themis Biosyn Makes ₹1,300 Crore Global Bet to Strengthen Biotech and CDMO Capabilities

Gujarat Themis Biosyn Ltd ($GUJTHEM) the has announced a major international expansion move by signing a definitive agreement to acquire 100% equity of Japan-based MicroBiopharm Japan Co., Ltd. (MBJ) through its wholly owned subsidiary, Themis Biosyn Japan Ltd. The acquisition, valued at JPY 21.5 billion (approximately ₹1,300 crore), will be funded through a combination of debt and equity and is expected to be completed in Q2 FY27, subject to regulatory approvals and customary closing conditions. MBJ specializes in research, development and manufacturing of APIs, intermediates and contract development and manufacturing (CDMO) services, with expertise in microbial fermentation, biotechnology-based manufacturing, oncology APIs, plasmid DNA production, ADC conjugation and enzyme-based bioconversion. The acquisition marks a strategic shift for GTBL from a fermentation-focused intermediates business to a technology-driven CDMO platform with advanced biotechnology capabilities. MBJ is estimated to generate revenue of JPY 9.5 billion (around ₹570 crore) in FY26, while its revenue stood at approximately ₹470 crore in FY23, ₹580 crore in FY24 and ₹560 crore in FY25. The transaction is not a related-party deal, and the promoter group has no interest in the acquired entity. This acquisition highlights GTBL’s ambition to strengthen its global presence and participate in the growing opportunities across biotechnology, precision fermentation and next-generation pharmaceutical manufacturing. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.